ERS 2026: GB-0895 clinical results show potential of next-gen anti-TSLP for asthma
At ERS 2026, Generate: Biomedicines investigators presented pharmacodynamics and safety results from the company’s ongoing Phase I study (NCT07116889) evaluating GB-0895.
Read the full article on the original site.
Read Full Article